NO20032781L - Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer - Google Patents

Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer

Info

Publication number
NO20032781L
NO20032781L NO20032781A NO20032781A NO20032781L NO 20032781 L NO20032781 L NO 20032781L NO 20032781 A NO20032781 A NO 20032781A NO 20032781 A NO20032781 A NO 20032781A NO 20032781 L NO20032781 L NO 20032781L
Authority
NO
Norway
Prior art keywords
laminin
overexpression
subunit
malignant tumors
diagnostic
Prior art date
Application number
NO20032781A
Other languages
English (en)
Other versions
NO20032781D0 (no
Inventor
Julia Y Ljubimova
Alexander V Ljubimov
Keith L Black
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of NO20032781D0 publication Critical patent/NO20032781D0/no
Publication of NO20032781L publication Critical patent/NO20032781L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Det beskrives en fremgangsmåte for diagnostisering av nærværet av maligne tumorer inkludert et gliom hos et menneskelig individ, der fremgangsmåten involverer å påvise overekspresjon av laminin-a4-subenhetprotein eller laminin-a4-spesifikk mRNA, sammenliknet med ekspresjonsnivået i en normal vevskontroll. Det beskrives videre en fremgangsmåte for forutsigelse av gjenopptredenen av en malign tumor hos et menneskelig individ, hvorfra en malign tumor er fjernet, og en fremgangsmåte for klassifisering av nivået av en malign tumor som en glial tumor, basert på en molekylær klassifisering.
NO20032781A 2000-12-19 2003-06-18 Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer NO20032781L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/741,550 US20020155440A1 (en) 2000-12-19 2000-12-19 Using overexpression of laminin alpha 4 subunit as a diagnostic and prognostic indicator of malignant tumors
PCT/US2001/050292 WO2002059610A2 (en) 2000-12-19 2001-12-19 Lamin alpha 4 subunit as a diagnostic indicator of malignant tumors

Publications (2)

Publication Number Publication Date
NO20032781D0 NO20032781D0 (no) 2003-06-18
NO20032781L true NO20032781L (no) 2003-08-18

Family

ID=24981166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032781A NO20032781L (no) 2000-12-19 2003-06-18 Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer

Country Status (7)

Country Link
US (1) US20020155440A1 (no)
EP (1) EP1356294A2 (no)
IL (1) IL156541A0 (no)
NO (1) NO20032781L (no)
PL (1) PL366317A1 (no)
WO (1) WO2002059610A2 (no)
ZA (1) ZA200305097B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US7877273B2 (en) * 2002-01-08 2011-01-25 Fredric David Abramson System and method for evaluating and providing nutrigenomic data, information and advice
WO2004048548A2 (en) * 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
CA2505784A1 (en) * 2002-11-25 2004-06-10 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
AU2003293130A1 (en) * 2002-11-25 2004-06-18 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US20050272043A1 (en) * 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
EP1660685A4 (en) * 2003-09-12 2008-07-02 Cedars Sinai Medical Center ANTISENSE INHIBITION OF LAMINININ-8 EXPRESSION FOR THE INHIBITION OF HUMAN GLIOMES
JP5008981B2 (ja) * 2003-12-05 2012-08-22 アロジーン， インコーポレイテッド ポリリンゴ酸ベースの多機能性薬物送達システム
US8911717B2 (en) 2003-12-05 2014-12-16 Cedars-Sinai Medical Center Polymalic acid-based multifunctional drug delivery system
US20050227225A1 (en) * 2004-04-07 2005-10-13 Roche Molecular Systems, Inc. Stabilization of biomolecules in samples
CA2567973A1 (en) * 2004-05-27 2005-12-15 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
EP2589961A3 (en) * 2006-09-06 2013-08-07 The Regents of the University of California Molecular diagnosis and classification of malignant melanoma
SG10201906494PA (en) * 2008-01-30 2019-09-27 Histogen Inc Extracellular matrix compositions
US8530415B2 (en) * 2008-01-30 2013-09-10 Histogen, Inc. Repair and/or regeneration of cells with a composition produced by culturing fibroblast cells under hypoxic conditions
US8535913B2 (en) * 2008-01-30 2013-09-17 Histogen, Inc. Soluble composition for promoting hair growth produced by hypoxic culture of fibroblasts cells
US8524494B2 (en) 2008-01-30 2013-09-03 Histogen, Inc. Low oxygen tension and BFGF generates a multipotent stem cell from a fibroblast in vitro
ES2424329T3 (es) * 2008-03-05 2013-10-01 The Regents Of The University Of California Diagnóstico molecular y clasificación de melanoma maligno
PT2451964T (pt) * 2009-07-10 2018-05-07 Histogen Inc Meio condiconado e composições de matriz extracelular de células cultivadas sob condições hipóxicas
WO2011072240A1 (en) 2009-12-10 2011-06-16 Cedars-Sinai Medical Center Drug delivery of temozolomide for systemic based treatment of cancer
US9623041B2 (en) 2010-12-30 2017-04-18 Cedars-Sinai Medical Center Polymalic acid-based nanobiopolymer compositions
AU2012239933B2 (en) * 2011-04-06 2017-01-05 Cedars-Sinai Medical Center Polymalic acid based nanoconjugates for imaging
CN107058596A (zh) * 2017-06-19 2017-08-18 上海市第十人民医院 一种与恶性胶质瘤诊断相关的标志物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
AU2001261519A1 (en) * 2000-05-12 2001-11-26 Fibrogen, Inc. Methods of affecting laminin 5 processing

Also Published As

Publication number Publication date
EP1356294A2 (en) 2003-10-29
ZA200305097B (en) 2004-08-12
IL156541A0 (en) 2004-01-04
WO2002059610A2 (en) 2002-08-01
US20020155440A1 (en) 2002-10-24
PL366317A1 (en) 2005-01-24
NO20032781D0 (no) 2003-06-18
WO2002059610A3 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
NO20032781L (no) Anvendelse av overekspresjon av laminin-alfa-4-subenhet som en diagnostiskog prognostisk indikator for maligne tumorer
KR101192297B1 (ko) 간암에 대한 신규 바이오마커 및 그의 용도
Ziober et al. Identification of a gene signature for rapid screening of oral squamous cell carcinoma
Zhou et al. Up-regulation of SERPINA3 correlates with high mortality of melanoma patients and increased migration and invasion of cancer cells
Hausladen et al. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome
Ruiter et al. Pathologic staging of melanoma
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
Wang et al. Fatty acid synthase as a tumor marker: its extracellular expression in human breast cancer.
Sodek et al. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT)
Kawai et al. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: a multicenter observational study
Yamashita et al. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis
Skuletić et al. Angiogenic and lymphangiogenic profiles in histological variants of papillary thyroid carcinoma
Li et al. Progranulin promotes lymphangiogenesis through VEGF-C and is an independent risk factor in human esophageal cancers
Soikkeli et al. Systematic search for the best gene expression markers for melanoma micrometastasis detection
Morelli et al. Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancers.
Di Monaco et al. Is sarcopenia associated with osteoporosis? A cross-sectional study of 262 women with hip fracture
Xi et al. RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer
Gurluler et al. The role of preoperative serum levels for Dickkopf-related protein 1 as a potential marker of tumor invasion in patients with stage II and III colon cancer
Egger et al. Clinicopathologic and survival differences between upper and lower extremity melanomas
Motegi et al. Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis
KR102356676B1 (ko) 아스프로신을 포함하는 췌장암 진단용 바이오마커 및 이의 이용
WO2010085124A3 (ko) 간암진단과 재발 및 생존 예측용 마커, 이를 포함한 키트 및 상기 마커를 이용한 간암환자 예후 예측
Kaba et al. Dickkopf-1 levels in Turkish patients with bladder cancer and its association with clinicopathological features
Kondoh et al. Gene expression signatures that classify the mode of invasion of primary oral squamous cell carcinomas
Yuan et al. Clinical significance of exosomal long noncoding RNA DANCR as a novel serum-based diagnostic and prognostic biomarker in osteosarcoma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application